Michael Severino, AbbVie president
AbbVie, riding the Aduhelm afterglow, handpicks beta amyloid drug for further R&D as it bails on tau
Although shrouded in controversy, the FDA’s approval of Biogen’s Aduhelm for Alzheimer’s disease has opened the floodgates for other drugmakers buying in on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
